As such, our data clearly outlined, not only the predominant role that PKCδ plays in TGFβ1-mediated α-SMA expression in NASH, but also that the exogenous administration of PKCδ inhibitor sufficiently blocked the TGFβ1 pathway and the effects of fibrosis. The gene discussed is PRKCD; the disease is metabolic dysfunction-associated steatohepatitis.